8622 — Huakang Biomedical Holdings Co Income Statement
0.000.00%
- HK$49.05m
- HK$16.12m
- CNY24.63m
Annual income statement for Huakang Biomedical Holdings Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 25.5 | 22 | 26.1 | 25.3 | 24.6 |
Cost of Revenue | |||||
Gross Profit | 17.9 | 14.7 | 16.5 | 16.9 | 15.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 24.7 | 33.3 | 29.9 | 28.3 | 30.4 |
Operating Profit | 0.73 | -11.3 | -3.8 | -2.95 | -5.73 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 0.658 | -11.4 | -3.9 | -3.01 | -5.78 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.284 | -11.6 | -4.22 | -3.08 | -5.78 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.284 | -11.6 | -4.22 | -3.08 | -5.78 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.284 | -11.6 | -4.22 | -3.08 | -5.78 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.001 | -0.025 | -0.011 | -0.008 | -0.014 |